Remarkable Q3 and YTD Results from BioSyent Inc.
BioSyent Inc. (TSXV: RX) has reported an impressive financial performance for the third quarter (Q3) and year-to-date (YTD) results, highlighting significant growth metrics. The company has seen substantial increases in its sales across various segments, showcasing its strength in the specialty pharmaceutical market.
Key Financial Highlights
For the three months ended September 30, 2025, the Canadian Pharma Sales reached an impressive CAD 9,864,254, marking a 19% increase compared to the same quarter in the previous year. This upward trend continued with total Company sales for YTD 2025 soaring to CAD 33,380,060, representing a 27% increase over the previous year.
International and Legacy Business Sales
International Pharma Sales also showcased remarkable growth, recording CAD 1,153,742 for Q3, reflecting a staggering 94% increase, and CAD 3,134,572 for YTD, up by 316%. The Legacy Business Sales surged to CAD 1,203,808 in Q3, an increase of 83% compared to Q3 2024, contributing to a total trailing twelve months (TTM) revenue of CAD 42,176,744.
Profitability and Earnings
BioSyent's ability to generate profitable operations is also evident in its EBITDA figures. The EBITDA for Q3 stood at CAD 3,632,399, a 27% year-on-year increase. Year-to-date, EBITDA for 2025 reached CAD 9,594,195, marking a 35% increase compared to the previous year. This steadfast growth reflects the company’s efficient management of operating expenses relative to its sales growth.
Net Income and Earnings Per Share (EPS)
Net income for Q3 also appears robust, with BioSyent reporting CAD 2,682,340, indicating a 16% increase from the previous year. The fully diluted EPS reflects this performance, reaching CAD 0.23 for Q3, which marks a 19% increase year-on-year. For YTD, the fully diluted EPS increased to CAD 0.61, a solid 28% growth.
Strategic Actions and Future Focus
Mr. René Goehrum, the President and CEO of BioSyent, expressed pride in the company’s performance. He noted that all business segments registered significant contributions to overall growth, with key products like FeraMAX® and Tibella® driving sales both in Canada and in international markets.
The acquisition of worldwide rights to Tibella® / Tibelia® has turned out to be advantageous, fulfilling expectations for profitable sales growth. As the company moves closer to the end of 2025, it remains optimistic about sustaining its growth trajectory into 2026, ensuring continued momentum across its operations.
Dividend Announcements
In line with its positive performance, BioSyent paid quarterly cash dividends of CAD 0.05 per common share throughout the year. A subsequent cash dividend has also been declared, further prioritizing shareholder returns.
Company Overview
Established on the TSX Venture Exchange under the symbol “RX”, BioSyent stands as a growth-oriented specialty pharmaceutical company focused on acquiring and developing innovative healthcare products to improve patient outcomes. With 11,262,282 common shares outstanding, their market approach is characterized by strong partnerships with healthcare professionals, enhancing product delivery through various business units.
Frequently Asked Questions
What are the main financial highlights of BioSyent for Q3 2025?
BioSyent reported CAD 9,864,254 in Canadian Pharma Sales for Q3 2025, a 19% increase year-on-year, and an EBITDA of CAD 3,632,399, marking a 27% increase.
How did international sales perform for BioSyent?
International sales saw a staggering 94% increase, totaling CAD 1,153,742 for Q3 2025, and a remarkable rise of 316% for YTD sales.
What growth has BioSyent reported in its legacy business?
The Legacy Business Sales reached CAD 1,203,808 in Q3 2025, an 83% increase compared to the same quarter in the previous year.
What dividends has BioSyent declared?
BioSyent has consistently paid quarterly dividends of CAD 0.05 per share and has declared a follow-up dividend for December 2025.
What is the strategic focus for BioSyent moving forward?
Looking ahead, BioSyent is committed to maintaining its growth momentum, focusing on improving existing product sales and continuing to innovate within the pharmaceutical market.